Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism. METHODS: In two double-blind, randomized trials, we compared dabigatran at a dose of 150 mg twice daily with warfarin (active-control study) or with placebo (placebo-control study) in patients with venous thromboembolism who had completed at least 3 initial months of therapy. RESULTS: In the active-control study, recurrent venous thromboembolism occurred in 26 of 1430 patients in the dabigatran group (1.8%) and 18 of 1426 patients in the warfarin group (1.3%) (hazard ratio with dabigatran, 1.44; 95% confidence interval [CI], 0.78 to 2.64; P=0.01 for noninferiority). Major bleeding occurred in 13 patients in the dabigatran group (0.9%) and 25 patients in the warfarin group (1.8%) (hazard ratio, 0.52; 95% CI, 0.27 to 1.02). Major or clinically relevant bleeding was less frequent with dabigatran (hazard ratio, 0.54; 95% CI, 0.41 to 0.71). Acute coronary syndromes occurred in 13 patients in the dabigatran group (0.9%) and 3 patients in the warfarin group (0.2%) (P=0.02). In the placebo-control study, recurrent venous thromboembolism occurred in 3 of 681 patients in the dabigatran group (0.4%) and 37 of 662 patients in the placebo group (5.6%) (hazard ratio, 0.08; 95% CI, 0.02 to 0.25; P<0.001). Major bleeding occurred in 2 patients in the dabigatran group (0.3%) and 0 patients in the placebo group. Major or clinically relevant bleeding occurred in 36 patients in the dabigatran group (5.3%) and 12 patients in the placebo group (1.8%) (hazard ratio, 2.92; 95% CI, 1.52 to 5.60). Acute coronary syndromes occurred in 1 patient each in the dabigatran and placebo groups. CONCLUSIONS: Dabigatran was effective in the extended treatment of venous thromboembolism and carried a lower risk of major or clinically relevant bleeding than warfarin but a higher risk than placebo. (Funded by Boehringer Ingelheim; RE-MEDY and RE-SONATE ClinicalTrials.gov numbers, NCT00329238 and NCT00558259, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For patients who are treated with dabigatran for secondary prevention, only the standard regimen of 150 mg twice daily has been studied. 310”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [310]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [310]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Self-citationAntithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., & Weg, J. G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,042
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Self-citation(2003) · New England Journal of Medicine · doi:10.1056/nejmoa035451 · Cited by 887
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Self-citationKearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationNewly identified events in the RE-LY trial
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1007378 · Cited by 688
Research works printed but not linked: 1
- 8. Cochrane Database Syst Rev 2000;3: CD001367.
Cited by
Items 201–300 of 1,000
Caldeira, D., Canastro, M., Barra, M., Ferreira, A., Costa, J. N., Pinto, F. J., & Ferreira, J. J. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.0985 · Cited by 39
Jennings, I., Kitchen, D. P., Keeling, D. M., Fitzmaurice, D. A., & Heneghan, C. J. (2014) · British Journal of Haematology · doi:10.1111/bjh.13070 · Cited by 36
“…good evidence that for patients with AF or venous thromboembolism (VTE) these new drugs are viable alternatives to warfarin (Connolly et al, 2009; Schulman et al, 2009, 2013; Bauersachs et al, 2010; Granger et al, 2011; Buller et al, 2012; Agnelli et al, 2013a,b; Giugliano et al, 2013;…”
BackgroundManagement of venous thromboembolism in cancer patients and the role of the new oral anticoagulants
Wharin, C., & Tagalakis, V. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.11.001 · Cited by 36
Cohen, A. T., Imfeld, S., Markham, J., & Granziera, S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.11.036 · Cited by 38
“1, in terms of the RRR for VTE [24,25,29–32].”
MethodBloemen, S., Zwaveling, S., Douxfils, J., Roest, M., Kremers, R., & Mullier, F. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.10.005 · Cited by 35
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations
Caterina, R. D., Ageno, W., Agnelli, G., Chan, N., Diener, H., Hylek, E. M., Raskob, G. E., Siegal, D. M., Verheugt, F. W. A., Lip, G. Y. H., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1675816 · Cited by 37
Direct oral anticoagulants for unusual‐site venous thromboembolism
Riva, N., & Ageno, W. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12480 · Cited by 35
Mai, V., Bertoletti, L., Cucherat, M., Mainbourg, S., Grangé, C., Provencher, S., & Lega, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214134 · Cited by 35
Pawar, A. M., Gagne, J. J., Gopalakrishnan, C., Iyer, G. S., Tesfaye, H., Brill, G. E., Chin, K., & Bykov, K. (2022) · JAMA · doi:10.1001/jama.2022.1920 · Cited by 34
Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation
Barnes, G. D., Kanthi, Y. M., & Froehlich, J. B. (2015) · Vascular Medicine · doi:10.1177/1358863x14566429 · Cited by 40
Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism
Giustozzi, M., Franco, L., Vedovati, M. C., Becattini, C., & Agnelli, G. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01878-x · Cited by 38
Oh, H. J., Ryu, K. H., Park, B. J., & Yoon, B. (2021) · Medicine · doi:10.1097/md.0000000000025216 · Cited by 34
Amin, A., Bruno, A. S., Trocio, J. N., Lin, J., & Lingohr-Smith, M. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1007210 · Cited by 37
Tornyos, A., Kehl, D., D’Ascenzo, F., & Komócsi, A. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.12.001 · Cited by 36
Direct Anticoagulants and Risk of Myocardial Infarction, a Multiple Treatment Network Meta-Analysis
Kupó, P., Szakács, Z., Solymár, M., Habon, T., Czopf, L., Haţegan, L., Csányi, B., Borbás, J., Tringer, A., Varga, G., et al. (2019) · Angiology · doi:10.1177/0003319719874255 · Cited by 35
“Combined antiplatelet therapy was allowed in 13 studies.(9,12,41,42,43,23-27,29,36,40) Analysis of bias showed high quality of the source information with low probability of possible bias.”
McBane, R. D., Loprinzi, C. L., Ashrani, A. A., Lenz, C. J., Houghton, D. E., Zemla, T., Le‐Rademacher, J. G., & Wysokiński, W. E. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13338 · Cited by 33
Wu, C. M., Alotaibi, G., AlSaleh, K. A., & McMurtry, M. S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.07.001 · Cited by 34
“Clinical trials have shown each of these agents to be at least as effective and safe as VKAs for the acute treatment of VTE and the secondary prevention of recurrent VTE [9–15].”
BackgroundMukdad, M. A., Al‐Badriyeh, D., & Elewa, H. F. (2019) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029619849103 · Cited by 34
Assessing the anticoagulant effect of dabigatran in children: An in vitro study
Dietrich, K. D., Stang, L. J., van Ryn, J., & Mitchell, L. G. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.01.017 · Cited by 32
Sipahi, İ., Çelık, S., & Tozun, N. A. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.12217 · Cited by 32
Riess, H. B., Ay, C., Bauersachs, R. M., Becattini, C., Beyer‐Westendorf, J., Cajfinger, F., Chau, I., Cohen, A. T., Khorana, A. A., Maraveyas, A., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0473 · Cited by 33
Prevention of venous thromboembolism in ambulatory patients with cancer
Khorana, A. A., Cohen, A. T., Carrier, M., Meyer, G., Pabinger, I., Kavan, P., & Wells, P. S. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000948 · Cited by 32
Kahale, L. A., Hakoum, M. B., Tsolakian, I. G., Matar, C. F., Barba, M., Yosuico, V. E. D., Terrenato, I., Sperati, F., Schünemann, H. J., & Akl, E. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006466.pub6 · Cited by 37
New Oral Anticoagulants in Patients With Cancer: Current State of Evidence
Sardar, P., Chatterjee, S., Herzog, E., Pekler, G., Mushiyev, S., Pastori, L. J., Visco, F., & Aronow, W. S. (2014) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000055 · Cited by 34
Dobrowolski, C., Clark, E. G., & Sood, M. M. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1437-1 · Cited by 33
Weitz, J. I., Jaffer, I., & Fredenburgh, J. C. (2017) · F1000Research · doi:10.12688/f1000research.11174.1 · Cited by 38
Direct oral anticoagulants: An update
Franco‐Moreno, A., Díaz, R. M. M., & Navarro, M. J. G. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.07.005 · Cited by 34
Elboudwarej, O., Patel, J. K., Liou, F., Rafiei, M., Osborne, A. D., Chai, W., Kittleson, M. M., Czer, L. S. C., Stern, L. K., Esmailian, F., et al. (2015) · Clinical Transplantation · doi:10.1111/ctr.12566 · Cited by 31
Caldeira, D., Gonçalves, N., Pinto, F. J., Costa, J. N., & Ferreira, J. J. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3791 · Cited by 31
Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence
Bracey, A., Shatila, W., & Wilson, J. M. (2018) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944718801554 · Cited by 31
Loffredo, L., Violi, F., & Perri, L. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.03.086 · Cited by 31
Wei, A., Gu, Z., Zhang, C., Ding, Y., Liu, D., Li, J., Liu, X.-Y., Lin, H., & Pu, J. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.05.048 · Cited by 31
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 33
Consistency of safety profile of new oral anticoagulants in patients with renal failure
Lega, J., Bertoletti, L., Gremillet, C., Boissier, C., Mismetti, P., & Laporte, S. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12486 · Cited by 29
Self-citationCove, C. L., & Hylek, E. M. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000136 · Cited by 32
Long-Term Management of Pulmonary Embolism: A Review of Consequences, Treatment, and Rehabilitation
Højen, A. A., Nielsen, P. B., Overvad, T. F., Albertsen, I. E., Klok, F. A., Rolving, N., Søgaard, M., & Ording, A. G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195970 · Cited by 32
“The patients were subsequently randomized to an active treatment or placebo (although two trials had an active treatment in the placebo arm) [34,36].”
BackgroundInfluentialBouman, A. C., ten Cate‐Hoek, A. J., Ramaekers, B. L. T., & Joore, M. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130531 · Cited by 30
Palareti, G. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.02.002 · Cited by 29
Novel oral anticoagulants: What dermatologists need to know
Plovanich, M., & Mostaghimi, A. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.11.013 · Cited by 30
National trends in hospitalizations for venous thromboembolism
Brahmandam, A., Abougergi, M. S., & Chaar, C. I. O. (2017) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2017.04.006 · Cited by 31
van Es, N., Wells, P. S., & Carrier, M. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.02.016 · Cited by 32
Halton, J. M., Picard, A.-C., Harper, R., Huang, F., Brueckmann, M., Gropper, S., Maas, H. J., Tartakovsky, I. S., Nurmeev, I. N., Mitchell, L. G., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-06-0429 · Cited by 30
Bertoletti, L., Benhamou, Y., Béjot, Y., Maréchaux, S., Cheggour, S., Aleil, B., Lellouche, N., Dillinger, J., & Delluc, A. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.01.002 · Cited by 30
Antithrombotic treatment for stroke prevention in atrial fibrillation: The Asian agenda
Chen, C.-H., Chen, M., Gibbs, H. H., Kwon, S. U., Lo, S. T., On, Y. K., Rosman, A., Suwanwela, N. C., Tan, R., Tirador, L. S., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.369 · Cited by 32
Ageno, W., Mantovani, L. G., Haas, S. K., Kreutz, R. H., Haupt, V., Schneider, J., & Turpie, A. G. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-16 · Cited by 29
“Direct oral Factor Xa inhibitors, such as apixaban, edoxaban and rivaroxaban, and the direct oral thrombin inhibitor dabigatran, have recently been investigated in phase III clinical trials for the treatment and secondary prevention of DVT and PE [8-15].”
The new oral anticoagulants: Reasonable alternatives to warfarin
Roca, B., & Roca, M. (2015) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.82a.14052 · Cited by 28
Extended anticoagulation after venous thromboembolism: should it be done?
Fernandes, C. J. C. D. S., Calderaro, D., Piloto, B. M., Hoette, S., Jardim, C., & Souza, R. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619878556 · Cited by 28
Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?
Weitz, J. I., Prandoni, P., & Verhamme, P. B. (2020) · TH Open · doi:10.1055/s-0040-1721735 · Cited by 35
Minno, M. N. D. D., Calcaterra, I. L., Papa, A., Lupoli, R., Minno, A. D., Maniscalco, M., & Ambrosino, P. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.04.004 · Cited by 29
Treatment with novel oral anticoagulants: indications, efficacy and risks
Ghanny, S., & Crowther, M. A. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328363c170 · Cited by 32
“In one trial, dabigatran was compared with warfarin (RE-MEDY); in the other, dabigatran was compared with placebo (RE-SONATE) [33].”
BackgroundMethodInfluentialAnticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach
Agnelli, G., & Becattini, C. (2015) · European Respiratory Journal · doi:10.1183/09031936.00164714 · Cited by 33
A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism
Comerota, A. J., & Ramacciotti, E. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.03.018 · Cited by 29
“Patients (N = 4,219) underwent randomization between the 2 extended-treatment trials—2,866 in RE-MEDY and 1,353 in RE-SONATE.”
MethodInfluentialAnticoagulation in Atrial Fibrillation – Current Concepts
Katritsis, D. G., Gersh, B. J., & Camm, A. J. (2015) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2015.04.02.100 · Cited by 36
“03),(39) and this was also observed in the recent Secondary Prevention of Venous Thromboembolism (RE-MEDY) trial.(40) However, in the recent Danish Registry report (4,978 patients on dabigatran and 8,936 patients on Figure 1: Choice of Anticoagulant for Atrial Fibrillation”
Harel, Z., Sood, M. M., & Perl, J. M. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000098 · Cited by 29
“Along similar lines both the RE-COVER [28], and its extension trial RE-MEDY [29], failed to detect a significant difference in recurrent VTE or VTErelated death, as well as bleeding events among users of dabigatran compared with warfarin [relative risk (RR) of recurrent VTE event or VTE-related death not estimable for…”
BackgroundResultInfluentialEthnoracial variations in venous thrombosis: Implications for management, and a call to action
Xu, Y., Siegal, D. M., & Anand, S. S. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15140 · Cited by 28
Anticoagulation Treatment in Venous Thromboembolism: Options and Optimal Duration
Diavati, S., Sagris, Μ., Terentes-Printzios, D. G., & Vlachopoulos, C. V. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666211111150705 · Cited by 32
Gómez‐Outes, A., Suárez-Gea, Lecumberri, R., Terleira‐Fernández, A. I., Vargas, E., & Rocha (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s35843 · Cited by 28
“15 Some studies with the new anticoagulants have assessed the issue of extending VTE treatment beyond 3–6 months in comparison with warfarin 105 or placebo, 61,76,105 but the percentage of patients with cancer included in these studies is very limited and further specific studies are needed.”
Succinct Review of the New VTE Prevention and Management Guidelines
Pollak, A. W., & McBane, R. D. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.11.015 · Cited by 28
Diagnose und Management der akuten pulmonalen Embolie: ESC-Leitlinien 2014
Saar, J. A., & Maack, C. (2015) · Herz · doi:10.1007/s00059-015-4378-0 · Cited by 30
Covert, K. L., & Branam, D. L. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa059 · Cited by 26
“test the efficacy of dabigatran vs warfarin for long-term VTE prophylaxis.(25)”
BackgroundMethodRecent developments in the diagnosis and treatment of pulmonary embolism
van der Hulle, T., Dronkers, C. E. A., Klok, F. A., & Huisman, M. V. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12404 · Cited by 28
Piazza, G. (2015) · Vascular Medicine · doi:10.1177/1358863x14568706 · Cited by 30
“20(2) 102 –104 © The Author(s) 2015 Reprints and permissions: sagepub.”
Applying ‘Patient Blood Management’ in the trauma center
Theusinger, O. M., Stein, P., & Spahn, D. R. (2014) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000041 · Cited by 26
Prandoni, P., Barbar, S., Milan, M., Vedovetto, V., & Pesavento, R. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.09.005 · Cited by 26
Zhang, Z., Zhai, Z., Yang, Y., Wan, J., Xie, W., Zhu, J., Shen, Y. H., & Wang, C. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1473-5 · Cited by 26
Anticoagulant Preferences and Concerns among Venous Thromboembolism Patients
Lutsey, P. L., Horvath, K. J., Fullam, L., Moll, S., Rooney, M. R., Cushman, M., & Zakai, N. A. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1625985 · Cited by 28
“16,17 DOACs are now widely used in clinical practice, 18,19 and are included — together with warfarin — as the standard of care for VTE treatment in current guidelines.”
Current Antithrombotic Treatments for Cardiovascular Diseases: A Comprehensive Review
Galanti, K., Marino, M. D., Mansour, D., Testa, S., Rossi, D., Scollo, C., Magnano, R., Pezzi, L., D’Alleva, A., Forlani, D., et al. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2508281 · Cited by 27
“Notably, the RE-MEDY study found that 150 mg of dabigatran given twice daily was associated with a higher recurrence risk compared to warfarin [99].”
BackgroundMethodResultInfluentialGreig, S. L., & McKeage, K. (2014) · Drugs · doi:10.1007/s40265-014-0304-7 · Cited by 27
“The RE-MEDY trial was similarly designed, but evaluated the noninferiority of dabigatran etexilate to warfarin for extended treatment for prevention of recurrent VTE, including death related to VTE [34].”
InfluentialWeitz, J. I., & Jaffer, I. (2016) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.3547 · Cited by 28
de Leeuw, K., Rutgers, A., Meijer, K., Tichelaar, V., & Howard, J. B. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1661387 · Cited by 29
Coulis, A. A., & Mackey, W. C. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.10.009 · Cited by 27
Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants
Bavalia, R., Middeldorp, S., Weißer, G., & Espinola–Klein, C. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1710314 · Cited by 26
Amin, A., & Marrs, J. C. (2015) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029615601492 · Cited by 28
Castellucci, L. A., Gal, G. L., Rodger, M. A., & Carrier, M. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12501 · Cited by 27
Transitions of care in anticoagulated patients
Michota, F. A. (2013) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s44068 · Cited by 29
Prins, M. H., & Lensing, A. W. A. (2013) · Thrombosis Journal · doi:10.1186/1477-9560-11-13 · Cited by 25
“85, respectively [26,27].”
Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism
Agnelli, G., & Becattini, C. (2013) · Hematology · doi:10.1182/asheducation-2013.1.471 · Cited by 27
Developments in the management and treatment of pulmonary embolism
Limbrey, R., & Howard, L. (2015) · European Respiratory Review · doi:10.1183/16000617.00006614 · Cited by 28
Changing Practice of Anticoagulation: Will Target-Specific Anticoagulants Replace Warfarin?
Arepally, G. M., & Ortel, T. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024633 · Cited by 27
Recio‐Boiles, A., Veeravelli, S., Vondrak, J., Babiker, H. M., Scott, A. J., Shroff, R. T., Patel, H., Elquza, E., & McBride, A. (2019) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v11.i10.866 · Cited by 25
Zhu, H., Zheng, H., Xu, T., Liu, X., Liu, X., Sun, L., Pan, X., Mai, W., Cai, X., & Huang, Y. (2021) · Vascular Pharmacology · doi:10.1016/j.vph.2021.106931 · Cited by 25
Who should get long-term anticoagulant therapy for venous thromboembolism and with what?
Rodger, M. A., & Gal, G. L. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020230 · Cited by 28
Bleeding and clotting in hereditary hemorrhagic telangiectasia
Dittus, C. E., Streiff, M., & Ansell, J. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i4.330 · Cited by 25
A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?
Güler, E., Güler, G. B., Demır, G. G., & Hatipoğlu, S. (2015) · The Anatolian Journal of Cardiology · doi:10.5152/anatoljcardiol.2015.6532 · Cited by 26
Treatment options for venous thromboembolism: lessons learnt from clinical trials
McRae, S. J. (2014) · Thrombosis Journal · doi:10.1186/s12959-014-0027-8 · Cited by 26
“Extended-duration dabigatran treatment has also been evaluated for the secondary prevention of VTE compared with both warfarin (RE-MEDY) and placebo (RE-SONATE) [38].”
BackgroundMethodResultInfluentialThe newer direct oral anticoagulants: a practical guide
Thachil, J. V. (2014) · Clinical Medicine · doi:10.7861/clinmedicine.14-2-165 · Cited by 25
NOACs for treatment of venous thromboembolism in clinical practice
Schulman, S., Singer, D. E., Ageno, W., Casella, I. B., Desch, M., & Goldhaber, S. Z. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-01-0065 · Cited by 24
Self-citationLusk, K. A., Snoga, J. L., Benitez, R. M., & Sarbacker, G. B. (2017) · Journal of Pharmacy Practice · doi:10.1177/0897190017707126 · Cited by 26
Bartoli-Abdou, J., Patel, J. P., Crawshaw, J., Vadher, B., Brown, A. H., Roberts, L. N., Patel, R., Arya, R., & Auyeung, V. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2017.12.021 · Cited by 24
Robertson, L., Yeoh, S. E., & Ramli, A. H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011088.pub2 · Cited by 29
Lanitis, T., Leipold, R., Hamilton, M., Rublee, D., Quon, P., Browne, C., & Cohen, A. T. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.01.020 · Cited by 23
New oral anticoagulants for the treatment of venous thromboembolism
Agnelli, G., Becattini, C., & Franco, L. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.07.005 · Cited by 23
Dobesh, P. P., & Fanikos, J. R. (2014) · Drugs · doi:10.1007/s40265-014-0301-x · Cited by 24
“Of the 2,856 patients in the RE-MEDY trial, 40 % were initially enrolled in the RE-COVER I or II trials, while only 2 % of the 1,343 patients in the RE-SONATE trial had been enrolled in these trials.”
BackgroundMethodInfluentialAspirin in the primary prophylaxis of venous thromboembolism in surgical patients
Sahebally, S. M., Healy, D. A., & Walsh, S. R. (2015) · The Surgeon · doi:10.1016/j.surge.2015.05.001 · Cited by 23
Discovery of Benzyl Tetraphosphonate Derivative as Inhibitor of Human Factor Xia
Kar, S., Mottamal, M., & Al‐Horani, R. A. (2020) · ChemistryOpen · doi:10.1002/open.202000277 · Cited by 23
Barbar, S., Milan, M., Campello, E., Spiezia, L., Piovella, C., Pesavento, R., & Prandoni, P. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-04-0396 · Cited by 26
“six months with VKAs for a first VTE were randomised to dabigatran (150 mg bid) or warfarin (INR 2–3) for the long-term prevention of recurrent VTE (66).”
BackgroundMethodTomkowski, W. Z., Kuca, P., Urbanek, T., Chmielewski, D., Krasiński, Z., Pruszczyk, P., Windyga, J., Oszkinis, G., Jawień, A., Burakowski, J., et al. (2017) · Acta Angiologica · doi:10.5603/aa.2017.0008 · Cited by 27
“In patients with low or moderate risk of bleeding complications, extended secondary VTE prevention using factor Xa inhibitors (apixaban, edoxaban, rivaroxaban), factor IIa inhibitors (dabigatran), VKA [1], or sulodexide (only DVT cases) is indicated [28].”
BackgroundUpdate on extended treatment for venous thromboembolism
Peñaloza-Martínez, E., Rodríguez, P. D., Proietti, M., Fernández‐Llamazares, G. S., Mendo, C. L., Álvarez-Sala, J. L., Marra, A. M., & del Toro‐Cervera, J. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1538564 · Cited by 26
“in the RE-SONATE and RE-MEDY trials [32].”
Huang, H., Peng, C. C., Lin, S., Munir, K. M., Chang, R. H., Wu, B., Liu, P. P., Hsu, J., Loh, C., & Tu, Y. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019618 · Cited by 23
Koval, N., Alves, M., Plácido, R., Almeida, A. G., Fonseca, J. E., Ferreira, J. J., Pinto, F. J., & Caldeira, D. (2021) · RMD Open · doi:10.1136/rmdopen-2021-001678 · Cited by 24
Metadata
- Authors
- Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z.
- Affiliations
- Karolinska University Hospital (SE)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Thrombosis Research Institute (GB)
- Krankenhaus Dresden-Friedrichstadt (DE)
- Sahlgrenska University Hospital (SE)
- Boehringer Ingelheim (Netherlands) (NL)
- Boehringer Ingelheim (Norway) (NO)
- Boehringer Ingelheim (United States) (US)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Brigham and Women's Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-21
- Volume
- 368
- Issue
- 8
- Pages
- 709-718
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2112378432
- Cited by
- 983
- References
- 25
- Citations by year
- 2026: 22 · 2025: 26 · 2024: 42 · 2023: 32 · 2022: 38 · 2021: 65 · 2020: 62 · 2019: 67 · 2018: 90 · 2017: 71 · 2016: 103 · 2015: 124 · 2014: 141 · 2013: 97
- FWCI
- 135.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- dabigatran, warfarin, venous thromboembolism, long-term anticoagulation, recurrent venous thromboembolism, major bleeding, acute coronary syndrome, direct oral anticoagulants, non-inferiority, thromboprophylaxis, thrombolysis, anticoagulant reversal
- MeSH terms
- Dabigatran, Adolescent, Adult, Aged, Aged, 80 and over, Benzimidazoles, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Recurrence, Risk, Warfarin, beta-Alanine, International Normalized Ratio, Venous Thromboembolism, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.